Pfizer seeks FDA approval for Xeljanz modified release tablets to treat RA

Pfizer is seeking approval from the US Food and Drug Administration (FDA) for its Xeljanz (tofacitinib citrate) 11mg once-daily modified release tablets to treat moderate-to-severe rheumatoid arthritis (RA) in patients with an inadequate response or …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news